Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry

Juan J Russo; Andrew T Yan; Stuart J Pocock; David Brieger; Ruth Owen; Karolina Andersson Sundell; Akshay Bagai; Christopher B Granger; Mauricio G Cohen; Satoshi Yasuda; Jose C Nicolau; Gunnar Brandrup-Wognsen; Dirk Westermann; Tabassome Simon; Shaun G Goodman

doi:10.1016/j.jjcc.2021.10.024

Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry

Standard

Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. / Russo, Juan J; Yan, Andrew T; Pocock, Stuart J; Brieger, David; Owen, Ruth; Sundell, Karolina Andersson; Bagai, Akshay; Granger, Christopher B; Cohen, Mauricio G; Yasuda, Satoshi; Nicolau, Jose C; Brandrup-Wognsen, Gunnar; Westermann, Dirk; Simon, Tabassome; Goodman, Shaun G.

In: J CARDIOL, Vol. 79, No. 4, 04.2022, p. 522-529.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Russo, JJ, Yan, AT, Pocock, SJ, Brieger, D, Owen, R, Sundell, KA, Bagai, A, Granger, CB, Cohen, MG, Yasuda, S, Nicolau, JC, Brandrup-Wognsen, G, Westermann, D, Simon, T & Goodman, SG 2022, 'Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry', J CARDIOL, vol. 79, no. 4, pp. 522-529. https://doi.org/10.1016/j.jjcc.2021.10.024

APA

Russo, J. J., Yan, A. T., Pocock, S. J., Brieger, D., Owen, R., Sundell, K. A., Bagai, A., Granger, C. B., Cohen, M. G., Yasuda, S., Nicolau, J. C., Brandrup-Wognsen, G., Westermann, D., Simon, T., & Goodman, S. G. (2022). Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J CARDIOL, 79(4), 522-529. https://doi.org/10.1016/j.jjcc.2021.10.024

Vancouver

Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA et al. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J CARDIOL. 2022 Apr;79(4):522-529. https://doi.org/10.1016/j.jjcc.2021.10.024

Bibtex

@article{8a401daba3d5420382646769e516a7e7,

title = "Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry",

abstract = "BACKGROUND: Patterns of dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI) have not been well studied.METHODS: TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 24 countries), observational study of patients 1 to 3 years post-MI. We sought to identify the prevalence and determinants of DAPT use ≥1 year post-MI in patients enrolled in TIGRIS. We used multivariable logistic regression to identify determinants of DAPT use at 396 days post-MI (365 days plus a 31day overrun period to account for intended DAPT discontinuation at 1 year). Patients treated with an oral anticoagulant were excluded.RESULTS: Of 7708 patients (median age 67 years, women 25%, ST-elevation MI 50%), 39% and 16% were on DAPT at 396 days and 5 years post-MI, respectively. DAPT use at 396 days post-MI was more prevalent in patients <65 years of age, treated with percutaneous coronary intervention (versus coronary artery bypass grafting or medical therapy), and with multivessel disease or a history of angina. Additional clinical determinants of ischemic and/or bleeding events following MI (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independently associated with DAPT use at 396 days. There were geographic variations in the use of DAPT at 396 days (p<0.001), with the lowest use in Europe and the highest in Asia and Australia.CONCLUSION: In a contemporary patient cohort, DAPT use beyond 1 year post MI was prevalent and associated with patient and index event characteristics. There were marked geographical variations in DAPT use beyond 1 year post MI.",

author = "Russo, {Juan J} and Yan, {Andrew T} and Pocock, {Stuart J} and David Brieger and Ruth Owen and Sundell, {Karolina Andersson} and Akshay Bagai and Granger, {Christopher B} and Cohen, {Mauricio G} and Satoshi Yasuda and Nicolau, {Jose C} and Gunnar Brandrup-Wognsen and Dirk Westermann and Tabassome Simon and Goodman, {Shaun G}",

note = "Copyright {\textcopyright} 2021. Published by Elsevier Ltd.",

year = "2022",

month = apr,

doi = "10.1016/j.jjcc.2021.10.024",

language = "English",

volume = "79",

pages = "522--529",

journal = "J CARDIOL",

issn = "0914-5087",

publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",

number = "4",

}

RIS

TY - JOUR

T1 - Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry

AU - Russo, Juan J

AU - Yan, Andrew T

AU - Pocock, Stuart J

AU - Brieger, David

AU - Owen, Ruth

AU - Sundell, Karolina Andersson

AU - Bagai, Akshay

AU - Granger, Christopher B

AU - Cohen, Mauricio G

AU - Yasuda, Satoshi

AU - Nicolau, Jose C

AU - Brandrup-Wognsen, Gunnar

AU - Westermann, Dirk

AU - Simon, Tabassome

AU - Goodman, Shaun G

PY - 2022/4

Y1 - 2022/4

N2 - BACKGROUND: Patterns of dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI) have not been well studied.METHODS: TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 24 countries), observational study of patients 1 to 3 years post-MI. We sought to identify the prevalence and determinants of DAPT use ≥1 year post-MI in patients enrolled in TIGRIS. We used multivariable logistic regression to identify determinants of DAPT use at 396 days post-MI (365 days plus a 31day overrun period to account for intended DAPT discontinuation at 1 year). Patients treated with an oral anticoagulant were excluded.RESULTS: Of 7708 patients (median age 67 years, women 25%, ST-elevation MI 50%), 39% and 16% were on DAPT at 396 days and 5 years post-MI, respectively. DAPT use at 396 days post-MI was more prevalent in patients <65 years of age, treated with percutaneous coronary intervention (versus coronary artery bypass grafting or medical therapy), and with multivessel disease or a history of angina. Additional clinical determinants of ischemic and/or bleeding events following MI (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independently associated with DAPT use at 396 days. There were geographic variations in the use of DAPT at 396 days (p<0.001), with the lowest use in Europe and the highest in Asia and Australia.CONCLUSION: In a contemporary patient cohort, DAPT use beyond 1 year post MI was prevalent and associated with patient and index event characteristics. There were marked geographical variations in DAPT use beyond 1 year post MI.

AB - BACKGROUND: Patterns of dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI) have not been well studied.METHODS: TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 24 countries), observational study of patients 1 to 3 years post-MI. We sought to identify the prevalence and determinants of DAPT use ≥1 year post-MI in patients enrolled in TIGRIS. We used multivariable logistic regression to identify determinants of DAPT use at 396 days post-MI (365 days plus a 31day overrun period to account for intended DAPT discontinuation at 1 year). Patients treated with an oral anticoagulant were excluded.RESULTS: Of 7708 patients (median age 67 years, women 25%, ST-elevation MI 50%), 39% and 16% were on DAPT at 396 days and 5 years post-MI, respectively. DAPT use at 396 days post-MI was more prevalent in patients <65 years of age, treated with percutaneous coronary intervention (versus coronary artery bypass grafting or medical therapy), and with multivessel disease or a history of angina. Additional clinical determinants of ischemic and/or bleeding events following MI (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independently associated with DAPT use at 396 days. There were geographic variations in the use of DAPT at 396 days (p<0.001), with the lowest use in Europe and the highest in Asia and Australia.CONCLUSION: In a contemporary patient cohort, DAPT use beyond 1 year post MI was prevalent and associated with patient and index event characteristics. There were marked geographical variations in DAPT use beyond 1 year post MI.

U2 - 10.1016/j.jjcc.2021.10.024

DO - 10.1016/j.jjcc.2021.10.024

M3 - SCORING: Journal article

C2 - 34857432

VL - 79

SP - 522

EP - 529

JO - J CARDIOL

JF - J CARDIOL

SN - 0914-5087

IS - 4

ER -